Penumbra (PEN) Cash & Current Investments (2014 - 2026)
Penumbra (PEN) posted quarterly Cash & Current Investments of $658.8 million for Q2 2026, up 55.17% year-over-year from $424.6 million in Q2 2025, and up 7.01% quarter-over-quarter from $615.7 million in Q1 2026.
Penumbra (PEN) Cash & Current Investments (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Cash & Current Investments for 13 consecutive years, with $658.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash & Current Investments rose 55.17% year-over-year to $658.8 million; the TTM figure through Jun 2026 stood at $658.8 million (up 55.17% YoY), while the FY2025 annual figure was $544.8 million, up 60.18% from the prior year.
- Cash & Current Investments rose to $658.8 million in Q2 2026 per PEN's latest filing, from $615.7 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $658.8 million in Q2 2026 and bottomed at $184.4 million in Q3 2022.
- Historically, Cash & Current Investments has averaged $341.8 million across 5 years, with a median of $302.2 million in 2024.
- Annual changes were most pronounced in 2022 — Cash & Current Investments slumped 30.91% — and 2026, when it surged 62.51%.
- Penumbra's Cash & Current Investments stood at $188.0 million in 2022, then soared by 53.8% to $289.2 million in 2023, then advanced by 17.62% to $340.1 million in 2024, then jumped by 60.18% to $544.8 million in 2025, then advanced by 20.92% to $658.8 million in 2026.
- Business Quant data shows PEN's Cash & Current Investments at $658.8 million in Q2 2026, $615.7 million in Q1 2026, and $544.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 5.60 Bn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 3.48 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 9.22 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 539.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 4.25 Bn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 1.95 Bn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 2.11 Bn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 3.32 Bn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 482.30 Mn |
| 10 | Penumbra | 12.79 Bn | 12.13 Bn | 264.94 Mn | 658.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 658.80 Mn |
| Mar 31, 2026 | 615.66 Mn |
| Dec 31, 2025 | 544.82 Mn |
| Sep 30, 2025 | 470.30 Mn |
| Jun 30, 2025 | 424.56 Mn |
| Mar 31, 2025 | 378.85 Mn |
| Dec 31, 2024 | 340.13 Mn |
| Sep 30, 2024 | 291.02 Mn |
| Jun 30, 2024 | 339.70 Mn |
| Mar 31, 2024 | 313.47 Mn |
| Dec 31, 2023 | 289.19 Mn |
| Sep 30, 2023 | 248.86 Mn |
| Jun 30, 2023 | 221.06 Mn |
| Mar 31, 2023 | 199.10 Mn |
| Dec 31, 2022 | 188.03 Mn |
| Sep 30, 2022 | 184.43 Mn |
| Jun 30, 2022 | 204.37 Mn |
| Mar 31, 2022 | 240.34 Mn |
| Dec 31, 2021 | 254.88 Mn |
| Sep 30, 2021 | 266.93 Mn |